The need for high-affinity, SARS-CoV-2-specific monoclonal antibodies (mAbs) is critical in
the face of the global COVID-19 pandemic, as such reagents can have important diagnostic …

Vaccines and therapeutics are urgently needed for the pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal …

The COVID-19 pandemic, once a global crisis, is now largely under control, a testament to
the extraordinary global efforts involving vaccination and public health measures. However …

A wide range of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
neutralizing monoclonal antibodies (mAbs) have been reported, most of which target the …

Infection with SARS‐CoV‐2 elicits robust antibody responses in some patients, with a
majority of the response directed at the receptor binding domain (RBD) of the spike surface …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has
necessitated the rapid development of antibody-based therapies and vaccines as …

The global coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has spawned an ongoing demand for …

The novel highly transmissible human coronavirus SARS-CoV-2 is the causative agent of
the COVID-19 pandemic. Thus far, there is no approved therapeutic drug specifically …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that
is spreading rapidly, which seriously impacts global public health and economy. Thus …

The Coronavirus disease 2019 (COVID-19) pandemic caused by Severe Acute Respiratory
Syndrome-Coronavirus-2 (SARS-CoV-2) is an ongoing threat to global public health. To this …